Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 13:96:e009.
doi: 10.1017/S0016672314000111.

Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases' community

Affiliations
Review

Organization for rare diseases India (ORDI) - addressing the challenges and opportunities for the Indian rare diseases' community

Harsha Karur Rajasimha et al. Genet Res (Camb). .

Abstract

In order to address the unmet needs and create opportunities that benefit patients with rare disease in India, a group of volunteers created a not-for-profit organization named Organization for Rare Diseases India (ORDI; www.ordindia.org). ORDI plans to represent the collective voice and advocate the needs of patients with rare diseases and other stakeholders in India. The ORDI team members come from diverse backgrounds such as genetics, molecular diagnostics, drug development, bioinformatics, communications, information technology, patient advocacy and public service. ORDI builds on the lessons learned from numerous similar organizations in the USA, European Union and disease-specific rare disease foundations in India. In this review, we provide a background on the landscape of rare diseases and the organizations that are active in this area globally and in India. We discuss the unique challenges in tackling rare diseases in India, and highlight the unmet needs of the key stakeholders of rare diseases. Finally, we define the vision, mission, goals and objectives of ORDI, identify the key developments in the health care context in India and welcome community feedback and comments on our approach.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Key stakeholders of rare diseases in India.

References

    1. Aronson J. K. (2006). Editor's view – rare diseases and orphan drugs. British Journal of Clinical Pharmacology 61, 243–245. - PMC - PubMed
    1. Ausems M. G., Verbiest J., Hermans M. P., Kroos M. A., Beemer F. A., Wokke J. H., Sandkuijl L. A., Reuser A. J. & van der Ploeg A. T. (1999). Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counseling. European Journal Human Genetics 7, 713–716. - PubMed
    1. Butler Tjaden N. E. & Trainor P. A. (2013). The developmental etiology and pathogenesis of Hirschsprung disease. Translational Research 162, 1–15. - PMC - PubMed
    1. Chakma J., Masum H., Perampaladas K., Heys J. & Singer P. A. (2011) Indian Vaccine Innovation: the case of Shantha Biotechnics. Globalization and Health 7, 9. - PMC - PubMed
    1. Christianson A. & Modell B. (2004). Medical genetics in developing countries. Annual Review of Genomics and Human Genetics 5, 219–265. - PubMed

MeSH terms